Glaucoma is a group of optic neuropathies associated with aging and sensitivity to intraocular pressure (IOP). Early progression involves retinal ganglion cell (RGC) axon dysfunction that precedes frank degeneration. Previously we demonstrated that p38 MAPK inhibition abates axonal dysfunction and slows degeneration in the inducible microbead occlusion model of glaucoma in rat. Here, we assessed the neuroprotective effect of topical eye delivery of the p38 MAPK inhibitor BIRB 796 in three models of glaucoma (microbead occlusion in rat and squirrel monkey and the genetic DBA/2 J mouse model) with distinct durations of IOP elevation. While BIRB 796 did not influence IOP, treatment over four weeks in rats prevented degradation of anterograde axonal transport to the superior colliculus and degeneration in the optic nerve. Treatment over months in the chronic DBA/2 J model and in the squirrel monkey model reduced expression and activation of p38 downstream targets in the retina and brain but did not rescue RGC axon transport or degeneration, suggesting the efficacy of BIRB 796 in preventing associated degeneration of the RGC projection depends on the duration of the experimental model. These results emphasize the importance of evaluating potential therapeutic compounds for neuroprotection in multiple models using elongated treatment paradigms for an accurate assessment of efficacy.
Glaucoma is the primary source of permanent sightlessness around the world1, and is second only to cataract in producing vision loss. Estimates suggest that by 2020 over 75 million individuals will have glaucoma and that more than 10 million of those will already suffer from irreversible blindness1,2,3. In glaucoma, stress associated with sensitivity to intraocular pressure (IOP) is transmitted at the optic nerve head, selectively targeting retinal ganglion cells (RGCs) and their axons4,5. While age is a key risk factor, IOP is the only modifiable risk factor and the singular focus for clinical intervention6. The use of topical IOP-lowering drugs is the first line treatment for glaucoma7. Glaucoma progression can be slowed by reducing IOP, however RGC degeneration (and vision loss) continues for many. For nearly half the patients with glaucoma taking medications to reduce IOP, the disease will continue to worsen6,8,9. Neurodegeneration in glaucoma is similar to other age-related neurodegenerative disorders like amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease in that axonal function is compromised prior to death of neurons10,11,12,13,14,15,16. Deterioration of anterograde transport from RGCs to central targets in the brain arises early in animal models of glaucoma; degradation is followed by somatic drop-out in the retina subsequent to axonal loss in the optic nerve17,18,19. Experimental interventions that preserve axonal transport can suspend or stop subsequent degeneration of axons and cell bodies20,21,22. Given this progression, it is appropriate that the identification of neuroprotective therapies that could abate disease progression by preserving RGC structure and function independently of IOP remains a high priority23.
In a previous study we showed that inhibition of p38 mitogen-activated protein kinase (MAPK) with Ro3206145 protected against RGC axonal transport deficits and axon loss in rats with induced elevations in IOP via microbead occlusion of the anterior chamber24. The p38 MAPKs are a family of serine/threonine protein kinases that become activated in response to physical stress or injury25,26,27. Of the four p38 MAPKs identified, p38α and p38β are ubiquitously expressed, while the expression of p38γ and p38δ is tissue-specific25. Once activated, p38 MAPK can activate by phosphorylation downstream targets to induce changes in gene expression via transcription factor activation, inflammatory cytokine production, apoptosis, cell survival, growth and/or differentiation pathways, tissue remodeling and maintenance of the cytoskeleton25,26,27. Activation of the p38 MAPK pathway has been implicated in rheumatoid arthritis, inflammatory bowel disease, cardiovascular disease, diabetes, osteoporosis, Alzheimer’s disease, Parkinson’s disease, and glaucoma28,29,30,31,32,33,34. Due to its role in inflammation, many p38 inhibitors have been developed, and they fall into two groups based on mechanism of action: orthosteric or ATP-competitive (e.g., SB-203580, Ro3206145) and allosteric or non-competitive (e.g., BIRB 796)35. BIRB 796 (doramapimod) binds to p38 MAPK and causes a conformational change so that ATP cannot bind27,35,36. It has a dissociation rate much slower than that of other p38 inhibitors, and shows a high selectivity to and a picomolar affinity for p38, suggesting BIRB 796 would be a long-lasting drug with fewer off-target effects27,35,36.
Here we assessed the neuroprotective effects of BIRB 796 in three species using two models of glaucoma, the DBA/2 J mouse—an inbred strain tending towards IOP elevation with age – and the inducible microbead occlusion model in rat and squirrel monkey (SM) eyes37,38,39. The use of different species and approaches to elevate IOP in this study was deliberate, as promising neuroprotective drugs should be tested in multiple animal models to “increase the likelihood of translation to large human clinical trials”16,40. In this study, microbead injection into the anterior chamber of rats elevated IOP for four weeks and reduced RGC axonal transport of cholera toxin subunit B from retina to the superior colliculus in vehicle-treated rats; BIRB 796 treatment prevented this reduction and protected RGC axons from degeneration in the optic nerve. In DBA/2 J mice, IOP increased over a 24-week treatment period causing a decrease in axonal transport to the SC in vehicle-treated eyes. Similarly, microbead-induced IOP elevations in squirrel monkey eyes for 29 weeks reduced anterograde transport to the lateral geniculate nucleus (LGN). Treatment with BIRB 796 did not prevent transport degradation, nor did it protect RGC axons in the optic nerve in either model. However, treatment did reduce expression of p38 downstream targets that increased with elevated IOP, suggesting BIRB 796 did reach the retinal projection in DBA/2 J mice and SMs.
To examine the neuroprotective effects of BIRB 796 in glaucoma, we chose three different species (mouse, rat and non-human primate) and two different methods to elevate IOP (microbead occlusion and genetic mutation). As seen in the experimental timelines for the three models we used (Fig. 1a), the inducible microbead occlusion model in rats was of short duration (4 weeks) compared to the genetic DBA/2 J model (24 weeks) and the inducible microbead occlusion model in squirrel monkeys (29 weeks). To move BIRB 796 forward as a neuroprotective treatment for a chronic disease like glaucoma, we wanted to show efficacy over longer treatment periods and in different animal models16,40. Figure 1b–d illustrates the experimental methodology of microbead injections, BIRB 796 treatment, and anterograde transport tracing for each model. One rat in the vehicle group and one mouse in the vehicle group expired prior to completion of the study. No other animals, regardless of treatment, showed signs of impairment or distress (itching or rubbing of the eye, eye closure, excessive grooming of the face, Anoxeria, decreased responsiveness, labored breathing, and/or sudden lethargy) during the study.
BIRB 796 protects anterograde transport following microbead injection in rats
Baseline IOP measurements in rats ranged from 20.1 ± 0.9 to 20.6 ± 0.5 mm Hg and were similar for vehicle and BIRB 796 groups (p = 0.7). Saline injection into the anterior chamber had no effect on IOP in vehicle-saline or BIRB 796-saline eyes, while microbead injection elevated IOP in all vehicle-microbead and BIRB 796-microbead eyes for the full 4-week treatment period (Fig. 2a). Microbead injection resulted in an elevation of 34.4% in vehicle-microbead eyes compared to vehicle-saline eyes (27.7 ± 1.9 vs. 20.6 ± 1.5 mm Hg; p = 0.005, Fig. 2b) and a 36.3% increase in BIRB 796-microbead eyes compared to BIRB 796-saline eyes (27.2 ± 2.3 vs. 19.9 ± 2.0 mm Hg; p = 0.01). Mean IOP of vehicle-saline eyes and BIRB 796-saline eyes was similar to each other and to naïve rats (20.1 ± 1.5 mm Hg; p = 0.9, Fig. 1b); IOP in BIRB 796-microbead eyes was similar to vehicle-microbead eye IOP (p = 0.8).
We evaluated transport of cholera toxin subunit B (CTB) from the retina to the superior colliculus (SC), the primary central projection for RGCs in rodents, in rats that received vehicle or BIRB 796 as anterograde axonal transport is compromised early in models of glaucoma4,41,42,43,44. We verified RGC uptake and initial transport of fluorescently labeled CTB in RGC axons from naïve, vehicle-saline, vehicle-microbead, BIRB 796-saline and BIRB 796-microbead retinas (Fig. 2c) and then quantified the degree of intact SC transport in retinotopic maps (Fig. 2d). Transport from vehicle-saline eyes to the SC was similar to that of BIRB 796-saline eyes and to naïve rat eyes, showing nearly complete transport across the retinotopic map (red colors).
Elevated IOP following microbead injection resulted in transport deficits in the SC of vehicle-microbead rats indicated in SC sections and by lack of representation in the retinotopic map (Fig. 2d). We observed fewer and smaller transport deficits in SCs from BIRB 796-microbead rats. When quantified (Fig. 2e), anterograde transport to the SC from BIRB 796-saline eyes (94.8 ± 3.4% intact transport) was similar to naïve eyes (93.2 ± 1.9% intact transport) and vehicle-saline eyes (91.8 ± 1.2%; p = 0.3). Transport from vehicle-microbead eyes was reduced to 48.8 ± 6.7% compared to vehicle-saline eyes (p < 0.001); BIRB 796 treatment attenuated this reduction, resulting in 87.9 ± 3.4% intact transport from BIRB 796-microbead eyes compared to BIRB 796-saline (p = 0.7). Compared to vehicle-microbead, BIRB 796 protected transport from BIRB 796-microbead eyes by 80% (p < 0.001).
BIRB 796 protects ganglion cell axons following microbead injection in rats
We counted RGC axons in naïve, vehicle-saline, vehicle-microbead, BIRB 796-saline and BIRB 796-microbead optic nerves as axon degeneration in the optic nerve follows anterograde transport dysfunction to RGC targets such as the SC and LGN in models of glaucoma4. Figure 3a shows a representative rat optic nerve montage used to count RGC axons within the entire montage using the AxonJ macro in Fiji45,46. Representative images from naïve (Fig. 3b), vehicle-saline and BIRB 796-saline optic nerve montages (Fig. 3c) all appeared similar, with distinct axon profiles tightly packed into axon bundles. Vehicle-microbead optic nerves showed degenerating axon profiles and glial hypertrophy (Fig. 3c). Axons from BIRB 796-microbead optic nerves looked similar to naïve, vehicle-saline or BIRB 796-saline nerves, with very few degenerating profiles. Axon number ranged from 85,141 to 97,319 axons in naïve nerves, 87,599 to 105,553 axons in vehicle-saline nerves, and from 81,794 to 100,501 axons in BIRB 796-saline nerves. These counts are similar to previously published axons counts for rats (74,212 to 98,272 axons)47. Mean axon number (Fig. 3d) in vehicle-saline nerves (96,257 ± 2,113 axons) and BIRB 796-saline nerves (90,668 ± 1,996 axons) was similar to counts from naïve nerves (92,169 ± 1,658 axons; p = 0.2). Elevated IOP reduced RGC axons by 13% in vehicle-microbead nerves to an average of 84,115 ± 1,062 axons (range of 80,568 and 89,808 axons) compared to vehicle-saline nerves (p = 0.0002, Fig. 3d). In contrast, mean axon number in BIRB 796-microbead nerves (90,668 ± 1,996 axons, range of 86,223 to 103,931 axons) was similar to BIRB 796-saline nerves (p = 0.5, Fig. 3d). Compared to vehicle-microbead, BIRB 796 protected RGC axons in BIRB 796-microbead optic nerves by 8% (p = 0.01).
BIRB 796 did not protect anterograde transport in DBA/2 J mice
DBA/2 J mice have mutations in two genes, Gpnmb and Tyrp1, which cause pigment dispersion and iris atrophy within the anterior chamber, resulting in increasing IOP with age37,48,49,50,51. Baseline IOP was similar for vehicle-treated mice and BIRB 796-treated mice (15.7 ± 0.1 and 15.6 ± 0.1 mm Hg, respectively; p = 0.8). IOP was significantly elevated (20.2%) compared to baseline IOP (red dotted line, Fig. 4a) in vehicle- and BIRB 796-treated mice by 5 months of age and remained elevated for the next 16 weeks (p < 0.001). Mean treatment IOP (Fig. 1a) in vehicle-treated mice (19.5 ± 1.0 mm Hg) and BIRB 796-treated mice (19.5 ± 0.9 mm Hg) increased 42.4% compared to respective baseline IOPs (Fig. 4b, p < 0.001). Treatment with BIRB 796 had no effect on mean treatment IOP compared to vehicle treatment (p = 0.9).
Colocalization of fluorescently labeled CTB and phosphorylated neurofilament-heavy (pNF-H) in RGC somas and axons in vehicle-treated and BIRB 796-treated DBA/2 J mice varied within groups from robust uptake and localization in axons to no uptake by RGCs and little to no localization in axons (Fig. 4c). Similarly, anterograde transport of CTB to the SC of vehicle-treated and BIRB 796-treated DBA/2 J mice varied from nearly complete to entirely absent (Fig. 4d, top panels). Quantification of CTB transport in the SC showed intact transport in vehicle-treated mice averaged 32.0 ± 6.8%, with a range of 89.8 to 0.8% (Fig. 4e). BIRB 796 treatment did not protect axonal transport to the SC in BIRB 796-treated mice (28.8 ± 6.0%, range of 95.9 to 0.3%) when compared to vehicle-treated mice (p = 0.7).
BIRB 796 did not protect ganglion cell axons in DBA/2 J mice
A representative DBA/2 J optic nerve montage used in counting RGC axons within the entire montage is shown in Fig. 5a. We measured optic nerve cross-sectional area (indicated by red line) in whole nerve montages using Fiji. Representative images of optic nerves from vehicle-treated and BIRB 796-treated DBA/2 J mice (Fig. 5c) showed disorganized axon bundles, degenerating axon profiles (arrowheads) and glial hypertrophy (asterisk) when compared to a 10-month-old DBA/2J-Gpnmb+/SjJ (D2 Control) optic nerve (Fig. 5b). Axon number ranged from 14,756 to 62,961 axons in vehicle-treated nerves and from 10,846 to 57,545 axons in BIRB 796-treated nerves. These counts are similar to previously published axons counts for DBA/2 J mice indicative of a range of degenerative states (~10,000 to 65,000 axons)46,52. BIRB 796 did not protect mean axon number in BIRB 796-treated nerves (37,696 ± 3,559 axons) when compared to vehicle-treated nerves (36,231 ± 3,235 axons; p = 0.4, Fig. 5d), nor did it effect cross-sectional nerve area (0.131 ± 0.005 mm2 versus 0.133 ± 0.004 mm2; p = 0.7, Fig. 5e).
BIRB 796 effectively reduces levels of p38 MAPK-related targets in DBA/2 J mice
We examined the levels of p38-related injury targets in the retina and SC of vehicle- and BIRB 796-treated DBA/2 J mice to determine if BIRB 796 reached our target tissue. Quantitative RT-PCR measurements showed a 59% reduction in mRNA encoding Bcl2-associated X protein (Bax) within the SC of BIRB 796-treated mice compared to vehicle-treated mice (p = 0.01, Fig. 6a). A similar reduction was seen in the retina however it was not significant (p = 0.22). Lipocalin-2 mRNA levels increased 203% (p = 0.0006, Fig. 6b) and ceruloplasmin increased 96% (p = 0.0003, Fig. 6c) in BIRB-treated retinas compared to vehicle-treated retinas while interleukin 1β (IL1β) decreased 57% in BIRB-treated retinas compared to vehicle-treated retinas (p = 0.007, Fig. 6d). Treatment with BIRB 796 had no effect on mRNA levels of these genes within the SC (p ≥ 0.08). Examining protein expression in SCs and retinas from DBA/2 J mice showed reduced immunolabeling for BAX (Fig. 6e) and lipocalin-2 (Fig. 6f) within BIRB-treated SCs compared to vehicle-treated SCs. In contrast, immunolabeling for ceruloplasmin (Fig. 6g) and interleukin 1β (Fig. 6h) in BIRB 796-treated retinas appeared similar to vehicle-treated retinas. Quantification of BAX levels in vehicle- and BIRB 796-treated SCs showed a 68% reduction in BAX levels in BIRB 796-treated SCs (p = 0.02, Fig. 6i). We observed a decrease of 64% in lipocalin-2 levels in BIRB 796-treated SCs when compared to vehicle-treated SCs (p = 0.001, Fig. 6j). Quantification of ceruloplasmin (Fig. 6k) and interleukin 1β (Fig. 6l) revealed BIRB treatment had no effect on protein levels compared to vehicle (p ≥ 0.7).
BIRB 796 did not protect anterograde transport following microbead injection in squirrel monkeys
Baseline IOP measurements in SMs ranged from 20.0 ± 0.4 to 23.7 ± 0.7 mm Hg with a mean of 21.3 ± 0.5 mm Hg and were similar for vehicle-treated and BIRB 796-treated SMs (p = 0.4). IOP was significantly elevated compared to baseline IOP (red dotted line, Fig. 7a) in vehicle-treated SMs after three microbead injections and in BIRB 796-treated SMs after four microbead injections; IOP remained elevated for 20–22 weeks (p ≤ 0.016). Mean treatment IOP (Fig. 1a) increased 36.6% compared to baseline IOPs (22.4 ± 2.3 mm Hg; p = 0.02, Fig. 7b) in vehicle-treated SMs (30.5 ± 1.2 mm Hg) and 49.1% to 30.0 ± 1.3 mm Hg in BIRB 796-treated SMs compared to baseline IOP (20.1 ± 1.7 mm Hg; p = 0.003, Fig. 7b). Treatment with BIRB 796 had no effect on mean treatment IOP compared to vehicle treatment (p = 0.8).
Unlike rodents, where nearly all RGC axons terminate in contralateral targets, RGC axons in SMs terminate to ipsilateral and contralateral targets in equal (50:50) proportion53. To examine RGC anterograde transport in SMs, we injected CTB-488 into left vitreous chambers and CTB-594 into right vitreous chambers (Fig. 1b) and quantified CTB transport to the lateral geniculate nucleus (LGN), the primary ganglion cell subcortical target in primates as previously described39. We verified RGC uptake and initial transport of CTB in whole-mounted retinas from vehicle-treated and BIRB 796-treated SMs (Fig. 7c). Colocalization of CTB and phosphorylated neurofilament-heavy (pNF-H) was similar in vehicle-treated and BIRB 796-treated SM retinas. Representative images of LGNs from vehicle-treated and BIRB 796-treated SMs (Fig. 7e) showed reduced anterograde transport due to elevated IOP when compared to the LGN of a SM that received saline injection instead of microbeads (Fig. 7d). Quantification of anterograde transport to the LGN (Fig. 7f) showed elevated IOP due to microbead injection reduced transport 43% to 49.3 ± 12.7% intact transport in vehicle-treated SMs and 57% to 37.7 ± 11.3% intact transport in BIRB 796-treated SMs. Treatment with BIRB 796 did not protect transport to the LGN when compared to vehicle treatment (p = 0.5). We observed similar transport deficits to the SC of vehicle-treated and BIRB 796-treated SMs; BIRB treatment did not protect transport to the SC (p = 0.3).
BIRB 796 did not protect ganglion cell axons following microbead injection in squirrel monkeys
A representative SM optic nerve montage used in counting RGC axons within the entire montage is shown in Fig. 8a. We measured optic nerve cross-sectional area (indicated by red line) in whole nerve montages using Fiji. Representative images of optic nerves from vehicle-treated and BIRB 796-treated SMs (Fig. 8c) showed numerous degenerating axon profiles, disorganized fascicles, and glial scarring, indicating axon degeneration and astrocyte hypertrophy when compared to when compared to saline eyes from a previous study (Fig. 8b)54,55. Comparing low magnification images of optic nerves from vehicle-treated and BIRB 796-treated SMs (Fig. 8d) to a nerve from a saline-injected eye showed vehicle-treated nerves appeared smaller than BIRB-796 treated nerves and saline nerves. Axon number ranged from 519,823 to 845,851 axons in vehicle-treated SM nerves and from 348,917 to 862,845 axons in BIRB 796-treated nerves. BIRB 796 did not protect mean axon number in BIRB 796-treated nerves (675,905 ± 112,427 axons) when compared to vehicle-treated nerves (672,596 ± 66,836 axons; p = 0.4, Fig. 8e). Optic nerve area decreased ~17% in vehicle-treated nerves (3.11 ± 0.21 mm2) when compared to BIRB 796-treated nerves (3.70 ± 0.3 mm2) but was not significant (p = 0.2, Fig. 8f).
BIRB 796 detected in vitreous and reduced activation of p38 MAPK downstream targets in squirrel monkey retina
We collaborated with the Vanderbilt Mass Spectrometry Research Center to measure drug content in SM vitreous samples using liquid chromatography–mass spectrometry (LC-MS). To determine the LC-MS signature for BIRB 796 and construct a calibration curve, we added known concentrations of BIRB 796 and ML-297, a reference standard, to SM vitreous humor samples and used LC-MS measure the ratio of peaks. The LC-MS signatures of BIRB 796 and ML-297 are shown in Fig. 9a. We found that detection of BIRB 796 in SM vitreous is remarkably linear and is predicted well by a broad range of applied concentrations from 2 nM up to 50 μM (Fig. 9b). Using this methodology, we detected measurable quantities of BIRB 796 within the linear range in vitreous humor samples from one SM that received two intravitreal injections of BIRB 796 (0.75%) in one eye and from one SM that received daily topical application of BIRB 796 (3%) for one week (Fig. 9c). As expected, the intravitreal injection produced a 6-fold higher concentration than topical dosing. We also detected stable levels of BIRB 796 in the vitreous of one SM after daily topical application of BIRB 796 (3%) for 9 weeks, with vitreous samples collected every 3 weeks (Fig. 9d). These data suggest BIRB 796 was able to penetrate into the eye when applied topically to the SM cornea. Next, we examined levels of phosphorylated p38 MAPK, phosphorylated MK2 and phosphorylated Hsp27 in retinas from vehicle- and BIRB 796-treated SMs to determine if BIRB 796 acts within our target tissue25,27. Phosphorylated p38 MAPK (pp38, Fig. 9e) appeared to localize to astrocytes and Műller glia end-feet in the NFL and to CTB + RGC somas in the GCL in vehicle- and BIRB-treated SM retinas. In vehicle-treated retinas, phosphorylated p38 also localized to the INL and to processes in the outer plexiform layer (OPL); this labeling appeared reduced in BIRB 796-treated retinas. Immunolabeling for phosphorylated MK2 (Fig. 9f) localized to CTB + RGCs and other nuclei in the GCL and to nuclei in the INL in vehicle- and BIRB-treated SM retinas. Treatment with BIRB 796 appeared to reduce pMK2 levels. Phosphorylated HSP27 (Fig. 9g) localized to Műller cell bodies and end-feet in vehicle- and BIRB 796-treated retinas. Again, treatment with BIRB 796 appeared to reduce pHSP27. Quantification showed BIRB 796 lowered phosphorylated p38 levels 29.8% in BIRB 796-treated retinas compared to vehicle-treated retinas (Fig. 9h); however, this was not significant (p = 0.2). Phosphorylated MK2 levels were reduced 43.8% in BIRB 796-treated retinas compared to vehicle-treated retinas (p = 0.04, Fig. 9i) and phosphorylated HSP27 levels decreased by 42.7% in BIRB 796-treated retinas compared to vehicle-treated retinas (p = 0.03, Fig. 9j).
We examined the neuroprotective effects of BIRB 796 in the DBA/2 J mouse and in rats and squirrel monkeys following microbead occlusion (summarized in Table 1). Daily topical treatment with BIRB 796 had no effect on IOP in any model but did protect anterograde transport to the rat SC and RGC axon degeneration in the rat optic nerve after 4 weeks of IOP elevation (Figs. 2 and 3). Unfortunately, treatment with BIRB 796 for 24 weeks in DBA/2 J mice or 29 weeks in SMs had no effect on anterograde transport to RGC targets or RGC axon survival in the optic nerve even though it decreased levels of p38 downstream targets in both models and was detected in SM vitreous after treatment. While data presented here implicate p38 MAPK in glaucomatous progression, BIRB 796 treatment for extended experimental periods did not protect RGC structure or function in the genetic and inducible glaucoma models used.
One potential reason for the lack of efficacy in the SM and DBA/2 J models presented here is drug availability in the ocular compartment following topical dosage. We did not perform pharmacokinetics or measure the levels of BIRB 796 in ocular tissues in rats or DBA/2 J mice, but we did detect BIRB 796 in SM vitreous samples after topical dosing for 9 weeks. Twice daily topical dosing in rats protected anterograde transport and RGC axons after 4 weeks of elevated IOP suggesting BIRB 796 was able to penetrate the ocular compartment and exert effects in rat retinas and/or optic nerves. Daily topical dosing over 24 plus weeks of elevated IOP in DBA/2 J mice and SMs did not protect RGC structure and function, but we did observe reduced expression of p38-related targets in treated DBA/2 J retinas and superior colliculi, and decreased activation of MK2 and Hsp27 in treated SM retinas. This would suggest BIRB 796 did reach the retina in DBA/2 J mice and SMs but failed to protect RGC axonal structure and function over longer treatment intervals.
Although BIRB 796 availability within the eye could account for the decreased efficacy observed in this study, a transient effect of p38 inhibitors has been observed previously. Due to the role of p38 MAPK in chronic inflammation, many p38 inhibitors have been developed and have advanced to clinical trials32. However, no p38 inhibitor has progressed past this phase and into market due to poor clinical efficacy, lack of sustained therapeutic effects, or adverse or off-target effects26,27,32,56,57. For example, Weisman et al. assessed VX-745 treatment in patients with rheumatoid arthritis (RA)58. Although the drug showed clinical efficacy and appeared well tolerated by patients over the 12 week treatment, VX-745 was withdrawn from clinical trials due to neurological adverse effects observed in a long-term animal trial27,57. A similar study using VX-702 treatment for RA showed no statistically significant difference between VX-702 and placebo treatment after 12 weeks, and reductions in inflammatory markers that were observed after one week of treatment had returned to baseline values by week 459. Cohen et al. examined the efficacy of the p38 inhibitor pamapimod in patients with RA60. Following 12 weeks of treatment, fewer patients had a clinical response to pamapimod when compared to the standard treatment for RA, higher doses of pamapimod showed twice the incidence of adverse effects, and reductions in inflammatory markers were observed early in the trial but were not sustained. Over the course of the trial, Cohen et al. found no decrease in plasma levels of pamapimod suggesting lack of efficacy was not due to metabolism of the drug60. In a 24-week trial of SCIO-469 in patients with RA, Genovese et al. found no significant differences in clinical efficacy when compared to placebo, and elevated liver enzymes were detected in patients treated at the higher dose of SCIO-46961. Much like previous trials, initial decreases in inflammatory markers returned to baseline levels prior to study end61. Similar results have been observed in clinical trials of p38 inhibitors in Crohn’s disease, cardiovascular disease, chronic obstructive pulmonary disease, cancer, and neurotic pain, where clinical efficacy was not achieved or sustained, and/or the study terminated due to adverse events62,63,64,65,66,67,68. Our results mirror those from clinical trials in that positive outcomes were not sustained over long treatment intervals. The most likely explanation for this may be the target itself.
The p38 MAPK pathway is activated by cellular stress and injury, making it an attractive target for therapeutic intervention in many diseases26. However, p38 activation can stimulate anti-inflammatory cytokines (e.g. IL-10) in addition to pro-inflammatory cytokines like TNFα and IL-1; hence inhibiting p38 MAPK in hopes of suppressing inflammation may actually activate inflammatory responses56,69. Further complicating the use of p38 inhibitors is evidence suggesting p38 MAPK can regulate cellular differentiation, migration, tissue homeostasis, and the cytoskeleton70,71. Inhibiting p38 from activating downstream targets that are anti-inflammatory and/or contribute to homeostasis could explain the poor efficacy observed in clinical trials. Another issue that could contribute to the lack of efficacy and/or a sustained effect of p38 inhibitors may be pathway regulation. Activation of p38 MAPK can occur via p38-specific signals, more general MAPK signals, or by MAPK kinase-independent signals where p38 autophosphorylates after binding accessory proteins or is phosphorylated at non-canonical sites25,70,72. These MAPK kinase-independent signals could result in inhibitors not binding all p38 MAPK present in the target tissue, leaving the pathway active. The MAPK pathway relies on feed-back loops for fine tuning, and inhibiting p38 could result in hyperactivation of upstream activating MAPK kinases, resulting in activation of other MAPK pathways56,73,74. For example, Jones et al. recently showed that p38 inhibition in synovial fibroblast cultures resulted in activation of NFκB, JNK, and MEK signaling in the presence of inflammatory cytokines75. This crosstalk suggests these signaling pathways are interconnected and may share common signals, such as CREB or phosphatases. Inhibition of JNK or MEK also caused activation of p38 signaling, but to a lesser degree than p38 inhibition had on those pathways75. Pathway crosstalk could be decoupled in the assay used by Jones et al., either by using multiple MAPK inhibitors, or by targeting kinases upstream of p38 or downstream substrates75. Much is known about MAPKs, yet cell- and tissue-specific responses to and the regulation of p38 MAPK in various contexts complicate its utility as a therapeutic target. Further work is needed to better understand how to modulate this pathway for effective clinical outcomes that can be sustained over long treatment periods without adverse effects.
The Vanderbilt University Institutional Animal Care and Use Committee approved all experimental procedures, which meet the standards and guidelines set forth in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals, Eighth Edition. We obtained male Brown Norway rats (7–9 months old) from Charles River Laboratories (Wilmington, MA) and randomly placed them into naïve (n = 4), vehicle (n = 9) or BIRB 796 (n = 9) groups. We obtained male DBA2/J mice (10 weeks of age) and DBA/2J-Gpnmb+/SjJ (D2 Control) from The Jackson Laboratory (Bar Harbor, ME). DBA2/J mice were randomly placed into vehicle (n = 20) or BIRB 796 (n = 20) groups. D2 Control mice (n = 4) were aged to 10 months. Rodents were maintained in a 12-hour light-dark cycle with standard rodent chow available ad libitum. We obtained male Bolivian squirrel monkeys (Saimiri boliviensis; 2–3 years of age) with no history of diabetes or head/eye trauma from the University of Texas MD Anderson Cancer Center (Bishop, TX). Squirrel monkeys (SMs) were socially housed, received environmental enrichment daily, and were maintained in a 12-hour light-dark cycle with standard primate biscuits and water available ad libitum. SMs were randomly placed into a vehicle (n = 2 SMs, 4 eyes) or BIRB 796 (n = 2 SMs, 4 eyes) group. No SM in either group showed signs of impairment or distress (itching or rubbing of the eye, eye closure, dehydration, Anorexia, lacerations, bites, or scratch wounds, abnormal gait or posture, head tilt, lethargy, swellings or growths, vomiting or diarrhea, or difficulty breathing) during the study. SMs from a previous cohort (n = 4) were used for BIRB 796 bioavailability studies (see below).
Intraocular pressure measurements
We measured intraocular pressure (IOP) bilaterally in awake rats (n = 9 per group) and in anesthetized (2.5% isoflurane) DBA/2 J mice (n = 20 per group) using a Tono-Pen XL rebound tonometer (Medtronic Solan, Jacksonville, FL) as previously described17,24. We measured IOP bilaterally in awake SMs (n = 4 eyes per group) using a Tono-Pen XL, a restraint tube, and positive-reinforcement training techniques as previously described39. We performed IOP measurements 2–3 times weekly in rodents and weekly in SMs following administration of 0.5% proparacaine hydrochloride ophthalmic solution (Patterson Veterinary Supply, Inc.) as a local anesthetic. IOP measurements began at least one week prior to treatment and concluded at least 48 hours prior to sacrifice. Naïve rats (n = 4) had one IOP measurement prior to CTB injection.
Microbead intracameral injection
In rats, we elevated IOP unilaterally by injecting 5.0 μl of 15 μm polystyrene microbeads (Molecular Probes, Eugene, OR) into the anterior chamber38. The fellow eye received an equivalent volume of saline to serve as an internal control. Rats (n = 9 per group) received one microbead or saline injection. Naïve rats (n = 4) did not receive a saline or microbead injection in either eye. We elevated IOP bilaterally in SMs by injecting 40 μl of 25–35 μm polystyrene microbeads (FP-30052-5; Spherotech, Inc., Lake Forest, IL) plus 1% Hydroxypropyl Methyl Cellulose (HPMC) in sterile phosphate buffered saline (PBS) into the anterior chamber using a 31-gauge needle attached to a syringe (Fisher Scientific) as described previously39. SMs (n = 2 per group, 4 eyes per group) received six microbead injections/eye over the 29-week treatment period.
BIRB 796 Preparation, treatment, and intraocular bioavailability
A 3% drug suspension of BIRB 796 (LC Laboratories, Woburn, MA) was prepared by adding 30 mg of BIRB 796 to 1 ml buffer [0.75% NaCl, 0.5% Hydroxypropyl methylcellulose (HMPC) viscosity 2600–5600 cP (Sigma Aldrich, St. Louis, MO), 0.5% sodium phosphate dibasic decahydrate (Fisher Scientific, Waltham, MA), 0.01% benzalkonium chloride (Sigma) in sterile water, pH 7.2, sterile filtered]. The suspension was vortexed for 30 seconds, placed in a water bath sonicator (Elma S30H, Elma Schmidbauer GmbH) and sonicated for 1 minute, and then vortexed again for 30 seconds. We repeated this process until no large pieces of drug were observed upon visual inspection of suspension. We prepared fresh vehicle and BIRB 796 suspensions twice a week (every 2 to 3 days). Vehicle (buffer with no BIRB 796 added) and BIRB 796 suspension were stored at 4 °C and kept on ice during dosing. Rats (n = 9 per group) received vehicle or BIRB 796 (10 μl per eye) applied topically to the cornea with a pipette twice daily, Monday through Friday, beginning at time of microbead injection and continuing for 4 weeks. Naïve rats (n = 4) did not receive a vehicle or BIRB 796 treatment. Mice (n = 20 per group) received BIRB 796 or vehicle (5 μl per eye) applied topically to the cornea with a pipette once daily, Monday through Friday, beginning at 12 weeks of age and continuing for 24 weeks. SMs (n = 2 per group, 4 eyes per group) received BIRB 796 or vehicle (40 μl per eye) applied topically to the cornea with a pipette once daily, Monday through Friday, beginning at time of microbead injection and continuing for 29 weeks. The dosing strategy used here resulted in compliance rates of 75% (21 doses of a possible 28) in rats, 71.4% (120 doses out of a possible 168) in mice, and 70.4% (143 doses out of a possible 203) in SMs. This level of compliance is similar to that of glaucoma patients using pressure-lowering medications (~70%)76,77,78,79,80. Animals were observed daily by authors or by Vanderbilt Division of Animal Care technicians for signs of distress and/or physical impairment. We also monitored changes in ocular tissues (e.g. opacity of the cornea, irritation of the conjunctiva).
For BIRB 796 bioavailability studies, we collected vitreous humor (50 μl/eye) from untreated SMs (n = 3 SMs, 6 eyes) by preparing, anesthetizing and monitoring SMs as described for Microbead Intracameral Injection previously39. We washed the eyes in sterile saline solution, and provided pre-emptive anesthesia using 0.5% proparacaine drops. We withdrew vitreous humor from the intravitreal cavity using a 31-gauge needle attached to a syringe and stored samples in sterile Fisherbrand 2.0 ml Microcentrifuge Tubes with Locking Snap Cap (Fisher Scientific) at −20 °C. Reversal of anesthesia and post-procedure monitoring were described previously39. While under anesthesia, one SM received 0.75% BIRB 796 (40 μl) via intravitreal injection into one eye using a 31-gauge needle attached to a syringe. A second intravitreal injection of BIRB 796 was performed into the same eye one week later, immediately before a second vitreous collection. Another SM from this group received 3% BIRB 796 (40 μl) applied topically to the cornea of one eye daily for one week. The third SM received no BIRB 796. One week after initial vitreous collection, we collected vitreous humor (50 μl/eye) from all SM eyes (n = 6) and stored samples at −20 °C. One SM (n = 1, 2 eyes) was treated bilaterally with 3% BIRB 796 (40 μl/eye) daily for 9 weeks; vitreous humor (50 μl/eye) was collected every 3 weeks. No SM in this cohort (n = 4) had more than three anesthetic events to collect vitreous humor or inject BIRB 796.
We collaborated with the Vanderbilt Mass Spectrometry Research Center with the goal of using liquid chromatography–mass spectrometry (LC-MS) to measure drug content in SM vitreous samples. ML297 (≥98%; Cayman Chemical, Ann Arbor, MI) was used as a reference standard. HPLC-grade acetonitrile (300 μl; JT Baker; VWR Scientific) was added to vitreous samples (100 μl), vortexed and centrifuged to remove any precipitated proteins or other particulates. Supernatant (300 μl) was removed, dried and reconstituted in 100 μl of the mobile phases of the LC (see below). We used a Surveyor HPLC system (Thermo-Fisher, Waltham, MA) consisting of a quaternary pump/degasser, refrigerated autosampler, and column heater to perform sample analyses. For chromatographic separations, we used a Poroshell 120 HPLC column (3.0 mm × 50 mm, 2.7 μm) (Agilent Technologies, Santa Clara, CA) equipped with an Acquity UPLC in-line stainless steel filter unit (0.2 μm, Waters Corp, Milford, MA). We set the column compartment temperature to 40 °C, and the autosampler tray temperature to 4 °C. Mobile phases were made up of 0.1% (v/v) formic acid (Fluka, 98%; Sigma-Aldrich. St. Louis, MO) in (A) HPLC-grade H2O (JT Baker; VWR Scientific) and in (B) HPLC-grade acetonitrile (JT Baker; VWR Scientific). We used the following gradient conditions: 0–1 min, B = 5%; 1–7 min, B = 5–95%; 7–9 min, B = 95%; 9.01 min, B = 5%; 9.01–11 min, B = 5%. The flow rate was maintained at 300 μL/min. The total chromatographic run time was 15 min. The sample injection volume was 10 μL. The autosampler injection valve and the sample injection needle were flushed with 400 μL methanol/water (2:1) containing 1% acetic acid between each injection. We performed tandem mass spectrometric detection using a TSQ Quantum triple-stage quadrupole mass spectrometer (Thermo-Fisher, Waltham, MA) equipped with a standard API-1 electrospray source and a 100 μm ID stainless steel capillary81. The instrument was tuned and calibrated every four to six weeks over a mass range of m/z 182 to m/z 997 with a mixture of tyrosine peptides using the manufacturer’s autotune procedure. The mass spectrometer was operated in positive ion mode. Quantitation was based on multiple reaction monitoring (MRM) detection of BIRB 796: m/z 528 → 256, CE 31 V and ML-297: m/z 329 → 200, CE 18 V. The following optimized parameters were used for the detection of analyte and internal standard: N2 sheath gas 40 psi; N2 auxiliary gas 5 psi; spray voltage 4.0 kV; capillary temperature 300 °C; capillary offset 35 V, tube lens offset 105 V, Ar collision gas 1.5 mtorr; scan time 100 ms; Q1/Q3 peak width at half-maximum 0.7 m/z. We performed data acquisition and quantitative spectral analysis using Thermo-Finnigan Xcalibur version 1.3 and Thermo-Finnigan LCQuan version 2.7, respectively. We constructed calibration curves by plotting peak area ratios (BIRB 796/ML-297) against BIRB 796 concentrations for a series of eight vitreal standards (3 nM – 50 μM). Each calibration level was processed in duplicate in order to determine the precision of the assay. A weighting factor of 1/C was applied in the linear least-squares regression analysis to maintain homogeneity of variance across the concentration range.
RNA extraction and quantitative RT-PCR
Mice (n = 5 for vehicle, n = 5 for BIRB 796) were sacrificed by cervical dislocation and retinas quickly extracted from the eye cups. We extracted total RNA from each retina (n = 10 per group) or SC (n = 10 per group) according to the SV Total RNA Isolation System kit protocol (Promega). RNA concentration and purity were determined using a NanoDrop 8000 (Thermo Scientific, Wilmington, DE). mRNA was then reverse-transcribed into cDNA using the 1st Strand cDNA Synthesis System for quantitative RT-PCR (Origene) following the manufacturer’s instructions. Reaction mixtures were diluted 3-fold and subjected to qRT-PCR amplification using AB 7300 Real Time PCR System (Applied Biosystem) and FastStart SYBR Green Master mix (Roche). Primers are listed in Table 2. Cycling conditions were the same for all primer sets: 94 °C for 2 minutes and 40 cycles of 94 °C for 30 seconds, 60 °C for 30 seconds, and 72 °C for 30 seconds. For each primer set, a dissociation curve was performed to confirm a single peak corresponding to a single product and no primer dimer. Relative product quantities for each transcript were performed in triplicate, normalized to GAPDH mRNA as an endogenous control, and determined using the comparative ΔCT method82.
CTB injection and anterograde axonal transport analysis
We anesthetized rats (n = 8 for vehicle, 9 for BIRB 796) and mice (n = 14 for vehicle, 15 for BIRB 796) with 2.5% isoflurane and intravitreally injected 2 µl (rat) or 1 µl (mice) of a 1% solution of cholera toxin subunit B (CTB) conjugated to Alexa Fluor-488 (Molecular Probes, CA) per eye as previously described18. Forty-eight hours later we perfused rodents transcardially with phosphate buffered saline (PBS) followed with 4% paraformaldehyde in PBS. We anesthetized SMs (n = 2 per group) using ketamine (Patterson Veterinary) plus dexmedetomidine (Patterson Veterinary) and maintained anesthesia with 2.5% isoflurane before intravitreally injecting 40 μl of a 1% solution of CTB-488 (left eyes) or CTB-594 (right eyes) using 31-gauge needle attached to a syringe39. We euthanized SMs using sodium pentabarbitol (Euthasol; Patterson Veterinary) via intravenous injection and transcardially perfused with PBS followed by 4% paraformaldehyde in PBS. Brains were cryoprotected in 20% sucrose/PBS (rodents) and 30% sucrose/PBS (SMs) and coronal midbrain sections (50–52 µm) cut on a Leica SM 2000R freezing sliding microtome (Leica Microsystems, Vienna, Austria) with a freezing stage (Brain Research Laboratories, Newton MA) and 250 mm flat back permanent microtome knife (C.L. Sturkey, Inc., Lebanon PA). We placed alternating sections of SC (rodents and SMs) and LGN (SMs) on Fisherbrand Superfrost Plus Microscope Slides (Fisher Scientific) and coverslipped with Fluoromount G (Southern Biotech, Birmingham, AL). We imaged rodent SC sections using a Nikon Ti Eclipse microscope at 4×(Nikon Instruments Inc., Melville, NY) and the intensity of CTB signal was quantified using a custom ImagePro macro (Media Cybernetics, Bethesda, MD) as previously described18. For SMs, we imaged SC and LGN sections using an Olympus FV-1000 inverted confocal microscope at 10x through the Vanderbilt University Medical Center Cell Imaging Shared Resource. We quantified the intensity of CTB-488 or CTB-594 signal in the SC and LGN using a custom ImagePro macro (Media Cybernetics, Bethesda, MD) after normalizing to background18. We calculated the percent of intact transport for each section as previously described39. We verified CTB uptake by RGCs in retinas from all groups using an Olympus FV-1000 inverted confocal microscope.
Optic nerve analysis
A 3 mm section of optic nerve (n = 8 nerves for naïve rat, vehicle-saline and vehicle-microbead rats, 9 nerves for BIRB 796-saline and BIRB 796-microbead rats; n = 8 nerves for D2 control, 17 nerves for vehicle-treated and 18 nerves for BIRB 796-treated DBA/2 J mice; n = 4 nerves vehicle-treated and 4 nerves BIRB 796-treated SMs) proximal to the globe was isolated, post-fixed for 1 hour in 4% paraformaldehyde (rodents) or 2 hours in 2% glutaraldehyde (SMs), and prepared for embedding and semi-thin cross-sectioning as described previously83. We incubated optic nerve segments in 2% osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA) in 0.1 M sodium cacodylate buffer (Electron Microscopy Sciences) for 1 hour then dehydrated samples in a graded ethanol series. We embedded optic nerve segments in Araldite 502 and Embed Resin 812 (Electron Microscopy Sciences). We collected optic nerve cross sections (0.7 μm) using a Leica Ultra Microtome EM UC7 (Leica Microsystems) and stained with 1% paraphenylenediamine (PPD; in a 1:1 mixture of methanol and 2-propanol) and 1% toluidine blue to identify myelin sheaths and glia, respectively. We imaged sections using 10x and 40×(SMs) or 100×(rodents) oil-immersion and differential interference contrast optics as a whole optic nerve montage with a microscope equipped with a motorized X-Y-Z stage and a digital SLR camera (Nikon H600L and DS-Ri2). We counted RGC axons within the entire optic nerve montage using the AxonJ macro in Fiji45,46 and measured ON cross-sectional area using Fiji.
Immunohistochemistry and image quantification
Whole eyes dissected from perfused rodents were prepared as whole-mount retinas (n = 4 retinas for naïve rats, n = 5 retinas for vehicle-saline and vehicle-microbead rats, 5 retinas for BIRB 796-saline and BIRB 796-microbead rats; n = 10 retinas for vehicle-treated and 10 retinas for BIRB 796-treated DBA/2 J mice), paraffin-processed (n = 8 eyes for vehicle-treated and 8 eyes for BIRB 796-treated DBA/2 J mice), or stored for later use (n = 10 eyes for vehicle-treated and 12 eyes for BIRB 796-treated DBA/2 J mice). For paraffin processing, we post-fixed eyes in 4% paraformaldehyde for 2 hours to overnight, then transferred to cassettes. We dehydrated eyes in a graded ethanol series followed by xylene clarification and three changes of paraffin (StatLab, McKinney TX) infusion before the final paraffin embedding. We collected sections (6 μm) using a Leica Ultra Microtome RM2255 (Leica Microsystems, Vienna, Austria). We dissected SM whole eyes (n = 4 eyes for vehicle-treated and 4 eyes for BIRB 796-treated) and bisected the retina, preparing one-half for whole-mount immunohistochemistry (n = 4 half-retinas for vehicle-treated and 4 half-retinas for BIRB 796-treated) and the other half for cryoembedding (n = 4 half-retinas for vehicle-treated and 4 half-retinas for BIRB 796-treated). We cryoprotected retinas in 10–30% sucrose/PBS followed by a 1:1 solution of 30% sucrose/PBS + Fisher Healthcare Tissue Plus OCT Compound (Fisher Scientific). We cryoembedded eyes in Fisher Healthcare Tissue Plus OCT Compound and collected sections (10 μm) using a CryoStar NX50 cryostat (ThermoFisher) and MX35 Premiere+ Microtome blades (ThermoFisher). We performed immunohistochemistry on paraffin sections, cryosections, and whole-mount retinas as previously described17,24. We blocked non-specific antibody binding with 5% normal donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), 0.1% Triton-X 100 (Sigma-Aldrich) and PBS + 0.02% sodium azide (Fisher Scientific). We diluted primary antibodies (Table 3) in 3% normal donkey serum, 0.1% Triton-X 100 and PBS + 0.02% sodium azide and incubated with sections or whole-mount retinas overnight at room temperature or 72 hours at 4 °C. Following three washes (15 minutes each) with PBS + 0.02% sodium azide, we incubated sections or whole-mount retinas with appropriate secondary antibodies (Table 3) 2 hours at room temperature or overnight at 4 °C. Following three washes (15 minutes each) with PBS + 0.02% sodium azide, we placed whole-mounted retinas on Fisherbrand Superfrost Plus Microscope Slides (Fisher Scientific) and coverslipped whole-mounted retinas, paraffin sections or cryosections with DAPI Fluoromount G (paraffin and cryosections) or Fluoromount G (whole-mounted retinas) (Southern Biotech, Birmingham, AL).
We imaged whole-mounted retinas using an Olympus FV-1000 inverted confocal microscope at 60 × (rodents) and 40×(SMs). For quantification, we imaged SC and retinal sections using an Olympus FV-1000 inverted confocal microscope at 60× resulting in images that were 512 × 512 pixels, 211.968 × 211.968 μm. Identical microscope settings were used to acquire images for quantification for a given protein of interest. We captured images in the mid-peripheral region of the retina for all vertical sections. One image per SC section or retinal vertical section was captured per DBA/2 J mouse (n = 12 for SC, n = 8 for retina). Two images were captured for each SM retinal vertical section, one on either side of the optic disc in the mid-peripheral region. Label was quantified in both images and the mean was used for quantification (n = 4 for retina for each group). A naïve observer quantified immunolabel in images using a custom macro in ImagePro (Media Cybernetics) that determines the percent area of the positive label18. Areas quantified for a protein of interest in SC or retinal sections did not differ between groups (p ≥ 0.2 for DBA/2 J, p ≥ 0.17 for SMs).
All data are expressed as mean ± standard error of the mean (SEM) unless indicated otherwise. The number of samples used in each experiment is provided in the appropriate methods section and figure legend. Statistical comparisons between two independent measurements were made using two-sided t-tests, following confirmation of normality for each using the Shapiro-Wilk normality test; samples for which normality failed were compared using the Mann-Whitney Rank Sum Test (SigmaPlot 14.0, Systat Software, Inc., Chicago, IL). Comparisons between multiple groups were made using one-way analysis of variance (ANOVA) followed by the Holm-Sidak Pairwise Multiple Comparison test (SigmaPlot 14.0) as described previously39.
All data generated or analyzed during this study are included in this published article; certain data have been reproduced for comparison where indicated from Lambert, W.S., Carlson, B.J., Ghose, P. et al. Towards A Microbead Occlusion Model of Glaucoma for a Non-Human Primate. Sci Rep 9, 11572 (2019) https://doi.org/10.1038/s41598-019-48054-y.
Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90, 262–267 (2006).
Cheung, W., Guo, L. & Cordeiro, M. F. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 85, 406–416 (2008).
Schober, M. S., Chidlow, G., Wood, J. P. & Casson, R. J. Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol 36, 377–385 (2008).
Calkins, D. J. Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog Retin Eye Res 31, 702–719 (2012).
Nickells, R. W., Howell, G. R., Soto, I. & John, S. W. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci 35, 153–179 (2012).
Heijl, A., Leske, M. C., Bengtsson, B., Hyman, L. & Hussein, M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120, 1268–1279 (2002).
Shih, G. C. & Calkins, D. J. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action. Expert Rev Ophthalmol 7, 161–175 (2012).
Investigators, T. A. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 130, 429–440 (2000).
Leske, M. C. et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121, 48–56 (2003).
Crish, S. D. & Calkins, D. J. Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience 176, 1–11 (2011).
McKinnon, S. J. The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. Invest Ophthalmol Vis Sci 53, 2485–2487 (2012).
Ghiso, J. A., Doudevski, I., Ritch, R. & Rostagno, A. A. Alzheimer’s disease and glaucoma: mechanistic similarities and differences. J Glaucoma 22(Suppl 5), S36–38 (2013).
Jindal, V. Glaucoma: an extension of various chronic neurodegenerative disorders. Mol Neurobiol 48, 186–189 (2013).
Danesh-Meyer, H. V. & Levin, L. A. Glaucoma as a neurodegenerative disease. J Neuroophthalmol 35(Suppl 1), S22–28 (2015).
Jain, S. & Aref, A. A. Senile Dementia and Glaucoma: Evidence for a Common Link. J Ophthalmic Vis Res 10, 178–183 (2015).
Levin, L. A., Crowe, M. E. & Quigley, H. A. Lasker, I. I. o. A. & Glaucomatous Neurodegeneration, P. Neuroprotection for glaucoma: Requirements for clinical translation. Exp Eye Res 157, 34–37 (2017).
Crish, S. D., Sappington, R. M., Inman, D. M., Horner, P. J. & Calkins, D. J. Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci U S A 107, 5196–5201 (2010).
Crish, S. D. et al. Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF prior to synapse loss in a central target. Neuroscience 229, 55–70 (2013).
Dengler-Crish, C. M. et al. Anterograde transport blockade precedes deficits in retrograde transport in the visual projection of the DBA/2J mouse model of glaucoma. Front Neurosci 8, 290 (2014).
Lambert, W. S., Ruiz, L., Crish, S. D., Wheeler, L. A. & Calkins, D. J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 6, 4 (2011).
Williams, P. A. et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355, 756–760 (2017).
Harun-Or-Rashid, M. et al. Structural and Functional Rescue of Chronic Metabolically Stressed Optic Nerves through Respiration. J Neurosci 38, 5122–5139 (2018).
Khatib, T. Z. & Martin, K. R. Protecting retinal ganglion cells. Eye (Lond) 31, 218–224 (2017).
Dapper, J. D., Crish, S. D., Pang, I. H. & Calkins, D. J. Proximal inhibition of p38 MAPK stress signaling prevents distal axonopathy. Neurobiol Dis 59, 26–37 (2013).
Zarubin, T. & Han, J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 15 (2005).
Genovese, M. C. Inhibition of p38: has the fat lady sung? Arthritis Rheum 60, 317–320 (2009).
Bagley, M. C., Davis, T., Murziani, P. G., Widdowson, C. S. & Kipling, D. Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. Pharmaceuticals (Basel) 3, 1842–1872 (2010).
Tezel, G., Chauhan, B. C., LeBlanc, R. P. & Wax, M. B. Immunohistochemical assessment of the glial mitogen-activated protein kinase activation in glaucoma. Invest Ophthalmol Vis Sci 44, 3025–3033 (2003).
Levkovitch-Verbin, H. et al. Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res 85, 250–258 (2007).
Seki, M. & Lipton, S. A. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res 173, 495–510 (2008).
Ray, A., Sehgal, N., Karunakaran, S., Rangarajan, G. & Ravindranath, V. MPTP activates ASK1-p38 MAPK signaling pathway through TNF-dependent Trx1 oxidation in parkinsonism mouse model. Free Radic Biol Med 87, 312–325 (2015).
Lee, J. K. & Kim, N. J. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease. Molecules 22 (2017).
Mammone, T., Chidlow, G., Casson, R. J. & Wood, J. P. M. Expression and activation of mitogen-activated protein kinases in the optic nerve head in a rat model of ocular hypertension. Mol Cell Neurosci 88, 270–291 (2018).
Akaiwa, K. et al. Topical Ripasudil Suppresses Retinal Ganglion Cell Death in a Mouse Model of Normal Tension Glaucoma. Invest Ophthalmol Vis Sci 59, 2080–2089 (2018).
Arai, T. et al. Design and synthesis of novel p38alpha MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety. Bioorg Med Chem Lett 22, 5118–5122 (2012).
Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9, 268–272 (2002).
Libby, R. T. et al. Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. Vis Neurosci 22, 637–648 (2005).
Calkins, D. J., Lambert, W. S., Formichella, C. R., McLaughlin, W. M. & Sappington, R. M. The Microbead Occlusion Model of Ocular Hypertension in Mice. Methods in molecular biology (Clifton, N.J.) 1695, 23–39 (2018).
Lambert, W. S. et al. Towards A Microbead Occlusion Model of Glaucoma for a Non-Human Primate. Sci Rep 9, 11572, https://doi.org/10.1038/s41598-019-48054-y (2019).
Ergorul, C. & Levin, L. A. Solving the lost in translation problem: improving the effectiveness of translational research. Current opinion in pharmacology 13, 108–114 (2013).
Linden, R. & Perry, V. H. Massive retinotectal projection in rats. Brain Res 272, 145–149 (1983).
Hofbauer, A. & Drager, U. C. Depth segregation of retinal ganglion cells projecting to mouse superior colliculus. J Comp Neurol 234, 465–474 (1985).
Crish, S. D. & Calkins, D. J. Central visual pathways in glaucoma: evidence for distal mechanisms of neuronal self-repair. J Neuroophthalmol 35(Suppl 1), S29–37 (2015).
Crish, S. D. & Schofield, B. R. Anterograde Tract Tracing for Assaying Axonopathy and Transport Deficits in Glaucoma. Methods in molecular biology (Clifton, N.J.) 1695, 171–185 (2018).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nature methods 9, 676–682 (2012).
Zarei, K. et al. Automated Axon Counting in Rodent Optic Nerve Sections with AxonJ. Sci Rep 6, 26559 (2016).
McKinnon, S. J. et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Molecular therapy: the journal of the American Society of Gene Therapy 5, 780–787 (2002).
John, S. W. et al. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 39, 951–962 (1998).
Chang, B. et al. Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat Genet 21, 405–409 (1999).
Anderson, M. G. et al. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 30, 81–85 (2002).
Inman, D. M., Sappington, R. M., Horner, P. J. & Calkins, D. J. Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest Ophthalmol Vis Sci 47, 986–996 (2006).
Howell, G. R. et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest 121, 1429–1444 (2011).
Erskine, L. & Herrera, E. Connecting the retina to the brain. ASN Neuro 6 (2014).
Quigley, H. A. & Addicks, E. M. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci 19, 137–152 (1980).
Almasieh, M., Zhou, Y., Kelly, M. E., Casanova, C. & Di Polo, A. Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis 1, e27 (2010).
Yong, H. Y., Koh, M. S. & Moon, A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 18, 1893–1905 (2009).
Goldstein, D. M., Kuglstatter, A., Lou, Y. & Soth, M. J. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53, 2345–2353 (2010).
Weisman, M, F. D. et al. In Annual European Congress of Rheumatology (Stockholm, Sweden, 2002).
Damjanov, N., Kauffman, R. S. & Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60, 1232–1241 (2009).
Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60, 335–344 (2009).
Genovese, M. C. et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38, 846–854 (2011).
Schildberg, F. W., Lohe, F. & Berger, H. Surgical relevance of diagnostic imaging in abdominal tumors–decision making in retroperitoneal tumors. Chirurg 68, 346–355 (1997).
Schreiber, S. et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4, 325–334 (2006).
Emami, H. et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis 240, 490–496 (2015).
Ostenfeld, T. et al. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy. Clin J Pain 31, 283–293 (2015).
Fisk, M. et al. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. PLoS One 13, e0194197 (2018).
Goldman, J. W. et al. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Invest New Drugs 36, 629–637 (2018).
Patel, N. R. et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 13, 1009–1019 (2018).
Ananieva, O. et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 9, 1028–1036 (2008).
Cuenda, A. & Rousseau, S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773, 1358–1375 (2007).
Cuadrado, A. & Nebreda, A. R. Mechanisms and functions of p38 MAPK signalling. The. Biochemical journal 429, 403–417 (2010).
Fisk, M., Gajendragadkar, P. R., Maki-Petaja, K. M., Wilkinson, I. B. & Cheriyan, J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am J Cardiovasc Drugs 14, 155–165 (2014).
Hall-Jackson, C. A., Goedert, M., Hedge, P. & Cohen, P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18, 2047–2054 (1999).
Davis, T., Brook, A. J., Rokicki, M. J., Bagley, M. C. & Kipling, D. Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts. Pharmaceuticals (Basel) 9 (2016).
Jones, D. S., Jenney, A. P., Joughin, B. A., Sorger, P. K. & Lauffenburger, D. A. Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. Sci Signal 11 (2018).
Barnebey, H. S. & Robin, A. L. Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Am J Ophthalmol 176, 61–69 (2017).
Dreer, L. E., Girkin, C. & Mansberger, S. L. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma 21, 234–240 (2012).
Hennessy, A. L., Katz, J., Covert, D., Protzko, C. & Robin, A. L. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology 117, 2345–2352 (2010).
Hermann, M. M., Papaconstantinou, D., Muether, P. S., Georgopoulos, G. & Diestelhorst, M. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Acta ophthalmologica 89, e300–305 (2011).
Schwartz, G. F. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 16, 114–121 (2005).
Iwamoto, H., Calcutt, M. W. & Blakely, R. D. Differential impact of genetically modulated choline transporter expression on the release of endogenous versus newly synthesized acetylcholine. Neurochem Int 98, 138–145 (2016).
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols 3, 1101–1108 (2008).
Ward, N. J., Ho, K. W., Lambert, W. S., Weitlauf, C. & Calkins, D. J. Absence of transient receptor potential vanilloid-1 accelerates stress-induced axonopathy in the optic projection. J Neurosci 34, 3161–3170 (2014).
Wu, C. et al. Different expression patterns of Bcl-2, Bcl-xl, and Bax proteins after sublethal forebrain ischemia in C57Black/Crj6 mouse striatum. Stroke 34, 1803–1808 (2003).
Steele, M. R., Inman, D. M., Calkins, D. J., Horner, P. J. & Vetter, M. L. Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma. Invest Ophthalmol Vis Sci 47, 977–985 (2006).
Defamie, V., Sanchez, O., Murthy, A. & Khokha, R. TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene 34, 4098–4108 (2015).
Tamura, Y. et al. Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice. Diabetes 62, 3170–3179 (2013).
We thank the Steve and Michelle Kirsch Foundation, Glaucoma Research Foundation, Research to Prevent Blindness, Inc., the Vanderbilt Vision Research Center Histology Core (supported by P30 EY08126), and Wade Calcutt and Brian Hachey from the Vanderbilt Mass Spectrometry Core Laboratory, Confocal imaging was performed through the use of the Vanderbilt Cell Imaging Shared Resource (supported by NIH grants CA68485, DK20593, DK58404, DK59637 and EY08126). Funding also provided by National Institutes of Health grants EY017427, EY024997 to D.J.C.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lambert, W.S., Pasini, S., Collyer, J.W. et al. Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma. Sci Rep 10, 8535 (2020). https://doi.org/10.1038/s41598-020-65374-6
Molecular Neurodegeneration (2021)